ESR1 and ovarian cancer: In suspended ovarian cancer cells, estrogen (E2) binding to its estrogen (E2) binding estrogen receptor alpha (ERα) blocks the anoikis-initiating release of PTRH2 from the mitochondria and FAs to the cytoplasm through a PI3K/AKT pathway.